99,500 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Zweig DiMenna Associates LLC

Zweig DiMenna Associates LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 99,500 shares of the company’s stock, valued at approximately $1,177,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC raised its position in shares of Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the period. State Street Corp increased its stake in Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC raised its holdings in Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after buying an additional 1,460,205 shares during the period. DME Capital Management LP lifted its stake in Roivant Sciences by 14.8% during the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after buying an additional 620,470 shares in the last quarter. Finally, TOMS Capital Investment Management LP acquired a new position in shares of Roivant Sciences in the third quarter worth about $46,333,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the sale, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. The trade was a 14.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,034,486 in the last quarter. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Performance

ROIV stock opened at $11.15 on Friday. The firm has a 50 day simple moving average of $11.75 and a 200 day simple moving average of $11.60. Roivant Sciences Ltd. has a 52 week low of $9.69 and a 52 week high of $13.06. The stock has a market cap of $8.12 billion, a P/E ratio of 1.98 and a beta of 1.27.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.